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Skin represents an attractive target for DNA vaccine delivery because of its natural richness in APCs, whose targeting may
potentiate the effect of vaccination. Nevertheless, intramuscular electroporation is the most common delivery method for ECTM
vaccination. In this study we assessed whether intradermal administration could deliver the vaccine into different cell types and
we analyzed the evolution of tissue infiltrate elicited by the vaccination protocol. Intradermal electroporation (EP) vaccination
resulted in transfection of different skin layers, as well as mononuclear cells. Additionally, we observed a marked recruitment of
reactive infiltrates mainly 6–24 hours after treatment and inflammatory cells included CD11c+. Moreover, we tested the efficacy
of intradermal vaccination against Her2/neu antigen in cellular and humoral response induction and consequent protection from
a Her2/neu tumor challenge in Her2/neu nontolerant and tolerant mice. A significant delay in transplantable tumor onset was
observed in both BALB/c (𝑝 ≤ 0,0003) and BALB-neuT mice (𝑝 = 0,003). Moreover, BALB-neuT mice displayed slow tumor
growth as compared to control group (𝑝 < 0,0016). In addition, while in vivo cytotoxic response was observed only in BALB/c
mice, a significant antibody response was achieved in both mouse models. Our results identify intradermal EP vaccination as a
promising method for delivering Her2/neu DNA vaccine.
1. Introduction
DNAvaccination is an attractive immunotherapeutic strategy
that triggers physiologic immunity and is able to induce long
lasting T cell and antibody-mediated tumor protection [1]. In
fact, direct injection into mouse muscle or skin of plasmid
DNA encoding a selected antigen results in the expression
of the gene product and can elicit an immune response
against the antigen of interest [2]. Currently, various delivery
devices such as gene-guns, bioinjectors, and electroporation
systems are being used in order to increase the potency of
DNA vaccines [3]. In vivo DNA electroporation (EP) has
emerged as an efficient delivery method that allows efficient
DNA uptake, long-term and high-level antigen expression
[4]. Furthermore, EP is also able to evoke the production
of several cytokines and chemokines, thereby increasing the
potency of DNA vaccines [4].
Muscle is the most commonly targeted tissue for evalu-
ation of EP in combination with DNA delivery [5]. Under
the influence of an electrical field, cellular membranes build
up a transmembrane potential until the dielectric strength of
the membrane is exceeded and permeation event occurs [6].
Intramuscular electroporation has been previously shown to
induce target antigen expression and to trigger humoral and
cellular immunity, thus enhancing tumor protection [7, 8]. EP
has been used clinically to deliver chemotherapeutic agents
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to tumor cells in cutaneous malignancies [9, 10]. Nowadays,
there are approximately 85 clinical trials listed using elec-
troporation (http://www.clinicaltrials.gov/): around 28 are
related to drug delivery and the rest are related to DNA
delivery [11–13]. Moreover, several data establish EP as a
potentmethod for stimulating immune responses induced by
DNA vaccination in humans [14, 15].
Skin is an attractive site for electroporation in transla-
tional settings, as it is readily accessible and EP is minimally
invasive and generally well tolerated [16], as compared to
muscle. Moreover, skin naturally harbors a high number
of antigen presenting cells (APCs), such as Langerhans
cells and other types of dermal dendritic cells, which after
DNA/antigen uptake can migrate to lymph nodes where
efficient presentation to T cells occurs [17, 18], thereby
potentially increasing EP efficacy.
The efficacy of intramuscular injection of a plasmid
coding for the extracellular and transmembrane domains
of the protein product of the Her-2/neu oncogene (ECTM)
followed by EP in transgenic murine models has been pre-
viously demonstrated [10]. The vaccination protocol induced
production of antibodies against Her-2/neu and IFN-𝛾 secre-
tion: these two immune activities were associated with the
clearance of Her-2/neu spontaneous lesions in transgenic
BALB-neuT mice [10]. However, sequential courses of DNA
intramuscular EPwere required tomaintain specific antibody
response and counteract the progression of preneoplastic
lesions to invasive carcinoma.
In the current study, we evaluated the effectiveness
of intradermal vaccination using EP against transplantable
Her2/neu+ tumor. To address this point, first we analyzed
intradermal EP vaccination-induced immune cell recruit-
ment, in both the skin and draining lymph nodes. Second, we
evaluated, in both Her2/neu tolerant (BALB-neuT) and non-
tolerant (BALB/c) mice, the ability of intradermal ECTM EP
vaccination to trigger Her2/neu specific immune responses
and counteract tumor onset and growth.
2. Material and Methods
2.1. Mice. Seven-week-old virgin female BALB/c and BALB-
neuTmice (H-2d)were used. BALB/cmicewere fromCharles
River Laboratories (Calco, Italy). Virgin BALB-neuT mice,
overexpressing the transforming rat Her-2/neu oncogene
under the control of the mouse mammary tumor virus [19],
were bred in house. Mice of the same age were randomly
assigned to experimental groups and were treated according
to the European Community guidelines.
2.2. Injection of Plasmids or FITC-Dextran and Electropora-
tion. pVAX (Invitrogen,Milan, Italy)was the backbone for all
the vaccines.The cDNA sequence for ECTMwas obtained as
previously described [19]. The pVAX-EGFP DNA construct
was obtained by subcloning the EGFP cDNA, excised from
pEGFP-N1 (Clontech, Mountain View, CA) by HindIII/XbaI
digestion, into the HindIII/XbaI sites of the pVAX-1 vector
(Life Technologies, Carlsbad, CA).The inserted sequencewas
verified by sequencing.
All plasmids for DNA immunizations were grown in
E. coli DH5𝛼 strain, and large-scale preparation of the
endotoxin-free plasmid DNA was carried out using Qiagen
EndoFree Plasmid-Giga kits (Qiagen, Chatsworth, CA, USA)
according to the manufacturer’s instructions. Endotoxin-free
plastic ware was used to prevent recontamination of the
plasmid.
Anesthetized mice were vaccinated with 50 𝜇L of solu-
tion containing 50𝜇g of DNA or 25mg/mL of fluores-
cein isothiocyanate-dextran (FITC-dextran) average mol wt
40,000 (Sigma Aldrich, Milan, Italy). The vaccination course
consisted of two intradermal injections into the skin of the
back near the base of the tail. Immediately after the plasmid
or FITC-dextran administration, a conducting gel and an
electrode were placed over the injection site and voltage
was set up according to previously described protocols (2
pulses, 1125V/cm 50 𝜇s, and 8 pulses, 275V/cm 10msec) [20].
Electrodes conslehisted of two parallel lamellae at 6–8mm
distance. Pulses were generated by an Igea Cliniporator (Igea,
Carpi, Italy). BALB/c and BALB-neuT mice were vaccinated
21 and 7 days before a subcutaneous injection with a lethal
dose of TUBO cells (day 0).
2.3. Cell Lines. Her-2/neu positive TUBO cells had been
originally isolated from a carcinoma arising in a BALB-neuT
mouse [21]. N202.1A (Her-2/neu positive) and N202.1E (Her-
2/neu negative) lines had been isolated from a mammary
carcinoma in a FVB/N mouse (H-2q) transgenic for the
rat Her-2/neu protoncogene [22]. TUBO cells were cultured
in DMEM (BioWhittaker Europe, Verviers, Belgium) with
20% FBS (Life Technologies, Inc., San Giuliano, Italy), and
N202.1A and N2021E in RPMI (BioWhittaker Europe) with
10% FBS (Life Technologies).
2.4. Tumor Challenge. Mice were subcutaneously injected
with 0.2mL of a single cell suspension containing the min-
imal lethal dose of TUBO (105) cells [19] in the right flank.
Mice were checked twice weekly for tumor onset: stable or
growing masses were regarded as tumors. Tumor growth
was evaluated twice weekly in a blind fashion. Neoplastic
masses weremeasured with calipers in the two perpendicular
diameters, and the tumor volume was recorded for 150 days.
At the end of this period, tumor-free mice were classified as
survivors. Mice were euthanized when the tumor exceeded
1 cm3 volume for humane reasons.
2.5. Antibody Response. Sera were collected 14, 30, 80, and
100 days after vaccination. 100 𝜇L of 1 : 10 diluted sera was
incubated for 45minutes at 4∘Cwith 2×105N2021Aor 1E cells
pretreated with Fc receptor blocker (CD16/CD32; Pharmin-
gen, Milan, Italy) for 15 minutes at 4∘C. Total Ig binding was
evaluated using a PE-conjugated goat anti-mouse Ig antibody
(DakoCytomation, Milan, Italy).The Ab4 (Oncogene, Milan,
Italy) was used as positive control for anti-Her2/neu reac-
tivity. Results were expressed as mean fluorescence intensity
(MFI) [23]. N202.1E MFI was subtracted to N202.1A MFI to
identify Her2/neu specific antibody reactivity and differences
in MFI were analyzed by Student’s 𝑡-test.
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Isotype determination was carried out by an indirect
immunofluorescence procedure. Dilutions (1 : 10) of sera in
PBS-azide-BSA were incubated for 45 minutes at 4∘C with 2
× 105 N202.1A or N202.1E cells, pretreated with Fc receptor
blocker (CD16/CD32; Pharmingen) for 15 minutes at 4∘C.
After washing, the cells were incubated for 30 minutes with
rat Alexa 488-conjugated antibodies anti-mouse IgM, IgG1,
IgG2a, IgG2b, or IgG3 (Invitrogen) and fluorescence evalu-
ated. The specific N202.1A-binding potential was calculated
as the percentage of MFI/total Ig.
Flow cytometry experiments were performed using a
FACSCalibur (Becton Dickinson, Milan, Italy) and analyzed
with FlowJo software (FlowJo LLC, Ashland, USA).
2.6. In Vivo Cytotoxicity Assay. In vivo cytotoxicity assay was
performed as previously described [24], with slight modifi-
cations. Briefly, a single-cell suspension of 107 naive spleno-
cytes (Spc)/mL was labeled with 0.5 (CFSElow) or 5𝜇mol/L
(CFSEhigh) of the carboxyfluorescein diacetate succinimidyl
ester CFSE (Molecular Probes, Leiden, Netherlands). Spc
labeled with 5 𝜇mol/L CFSE were also pulsed with 15 𝜇g/mL
of H-2K dominant Her2/neu (TYVPANASL) (Inbios SRL,
Naples, Italy) peptide for 1 hour at room temperature. The
two Spc populations were mixed together in equal amounts
and injected i.v. into control and treated mice. Mice were
sacrificed 48 hours later, and single-cell suspensions from
spleens were processed individually to evaluate the presence
of CFSEhigh cells with the FACSCalibur after adding pro-
pidium iodide to exclude dead cells. The specific cytolytic
activity was calculated as 100 × (percentage CFSElow cells −
percentage CFSEhigh cells)/percentage CFSElow cells.
2.7. Immunohistochemistry and Immunofluorescence. For
immunohistochemical evaluation, mice were euthanized
at 3, 6, 24, 48, 72, and 96 hours after vaccination and the
skin and axillary, inguinal, and popliteal lymph nodes were
collected, fixed in PFA 1%, and embedded in OCT and tissue
sections were stained with hematoxylin and eosin (H&E)
for histological examination. Skin and lymph nodes sections
were incubated with the following primary antibodies: rat
mAb anti-CD4, anti-CD8𝛼, anti-CD11b, anti-CD45R/B220,
anti-Gr-1 (BDPharmingen,Milan, Italy), anti-CD68 (Abcam,
Cambridge, UK), and anti-CD11c (Chemicon International,
USA). After washing, slides were overlaid with appropriate
secondary antibodies. Immunostaining was developed with
Vulcan Fast Red (Biocare, Milan, Italy) alkaline phosphatase
method. For immunofluorescence, secondary antibodies
conjugated with Alexa 488 and Alexa 546 (Invitrogen, Life
Technologies, Monza, Italy) were used. Nuclei were stained
with DRAQ5 (Alexis, Life Technologies, Monza, Italy), YO
PRO-3, or TO PRO-3 (Molecular Probes, Monza, Italy).
Image acquisition was performed using Zeiss LSM 510 Meta
confocal microscope (Carl Zeiss SpA, Milan Italy).
The slides were examined in a double-blind fashion, and
digital images of representative areas were taken.
2.8. Statistics. Quantitative data are presented as mean ±
SEM from three independent experiments. The significance
of differences was evaluated with two-tailed Student’s 𝑡-test
or log-rank (Mantel-Cox) test. Statistical analysis was carried
out with GraphPad Prism5 Software (San Diego, CA, USA);
𝑝 ≤ 0.05 was used as the critical level of significance.
3. Results
3.1. Intradermal EP Vaccination Results in a Marked Recruit-
ment of Reactive Infiltrates. To analyze the cellular effects of
vaccination, intradermal injection of FITC-dextran followed
by EP was performed in BALB/c mice. Immediately after
vaccination (3 hours) skin showed tissue damage and a
coagulated aspect as well as evident inflammatory infil-
trate (Figure 1(a)). Immunofluorescence analysis revealed the
presence of CD11b macrophages with incorporated FITC-
dextran (Figures 1(b)–1(d)) in close proximity of the dam-
aged area as well as in epidermis (Figure 1(b)), dermis
(Figure 1(c)), and hypodermis (Figure 1(d)). At this extremely
early time point, no cells with encapsulated FITC-dextran
were detected in lymph nodes (not shown). At a later time
point (6 hours after vaccination), CD11c cells with incorpo-
rated FITC-dextranwere detected in the dermis (Figure 1(e)).
Additionally, FITC-dextran was also incorporated by Lyve
1 lymphatic endothelial cells (Figure 1(f)) and deposited
outside CD31 blood vessels (Figure 1(g)). Some cells with
incorporated FITC-dextran were found into inguinal lymph
nodes (draining lymph nodes) (Figure 1(h)). No FITC-
dextran incorporating cells were detected in control mice
intradermally injected without electroporation. Altogether
these data are consistent with an efficient transfection of
APCs and their progressivemigration through the skin layers
to lymph nodes.
Accordingly, immunohistochemistry analysis highlight-
ed the accumulation of granulocytes (Gr1) and macrophages
(CD11b) 3 hours after treatment (Table 1) and a significant
number of reactive cells were still observed at 6 hours. In
particular, at this time point, dendritic cells (CD11c) and T
lymphocytes (CD4) were detected (Table 1 and Figures 2(a)
and 2(b)). Twenty-four hours after vaccination the number
of dendritic and CD4 cells decreased until almost baseline
levels (Table 1 and Figures 2(c) and 2(d)) and the local
inflammatory infiltrate gradually turned off starting at 48
hours after vaccination.
In order to shed light into themechanisms underlying the
immune responses elicited by the intradermal vaccination,
we analyzed the type and the localization of pVax EGFP
transfected cells in both skin and inguinal draining lymph
nodes (Figure 3). After an intradermal injection probably the
major part of the volume is deposited in the dermis due to
the epidermis being very thin, particularly in mice. However,
twenty-four hours after vaccination, positive cells have also
been found in epidermis and in the subcutaneous muscle
layer, the panniculus carnosus, near the damaged zone
(Figure 3(a)). Close to them, some infiltrating cells expressed
the transgene too (Figure 3(a)). As shown inTable 1, dendritic
cells decreased in skin 24 hours after treatment, so we inves-
tigated the presence of these cells in draining lymph nodes.
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Figure 1: Electroporation effect on FITC-dextran expression and distribution in skin.Three hours after intradermal injection of FITC-dextran
followed by EP reactive cells that are recruited (a). Among these CD11b (red) cells incorporate FITC-dextran and are found in different skin
layers ((b), (c), (d)). Six hours after vaccination, CD11c (red (e)) Lyve 1 (lymphatic vessel, red (f)) and CD31 (endothelial vessels, red (g)) cells
are detected in the skin. FITC-dextran and nuclei are shown in green and blue, respectively ((b)–(g)). FITC-dextran incorporating cells are
observed in draining lymph nodes 6 hours after treatment (h). Nuclei are shown in red (h). Images are representative of three independent
experiments. Magnification: (a), (b) ×200; (c), (d), (f), (g) ×630; (e) ×1500; (h) ×200, insert ×400.
Table 1: Semiquantitative analysis of inflammatory cells present
in the skin of BALB/c mice from 3 to 96 hours after pVAX-EGFP
vaccination followed by electroporation.
Time after
intradermal
EP vaccination
Gr-1 CD11b CD68 CD11c CD4 B220 CD8
3 h +++ +++ ++ + + −/+ −
6 h ++ +++ ++ ++ +++ + −/+
24 h ++ ++ + + ++ + −/+
48 h + ++ + −/+ + ++ −
72 h + ++ + −/+ + ++ −
96 h −/+ ++ + −/+ −/+ ++ −
The expression of reactive cells was defined as absent (−), scarcely (−/+),
moderately (+), frequently (++), or strongly (+++) present on cryostat
sections stained with the antibodies.
Not only transfected dendritic cells were found (Figure 3(b)),
but also, in accordance with their APC role, these cells
were transfected and in very tight proximity with both CD4
(Figure 3(c)) and B220 (Figure 3(d)).
3.2. Intradermal EP Vaccination Protects against a Lethal
Tumor Challenge by Inducing Her2/neu Specific CTLs and
AntibodyResponse. Intradermal ECTMEPvaccination effec-
tively delayed tumor onset in both Her2/neu nontolerant
and tolerant mice. In fact, while mice vaccinated with an
empty plasmid developed tumor within 30 days (Figures 4(a)
and 4(c)), in pVAX-ECTM treated group, all BALB/c mice
remained tumor free until the endpoint (Figures 4(a) and
4(b)), andBALB-neuTmice displayed a strong delay in tumor
onset (𝑝 = 0,003) (Figure 4(c)).
Notably, tumor growth in thesemicewas characterized by
very slow kinetics as compared to pVAX group (𝑝 < 0,0016)
(Figure 4(d)).
In accordance with the observed total protection against
tumor challenge, higher CTL activity was observed in
BALB/cmice electroporatedwith pVAX-ECTMplasmid (𝑝 =
0,0369), while no cytotoxicity was detected in Her2/neu
tolerant BALB-neuT mice (Figure 5(a)). This data together
with a higher protection observed in Balb-cmice is consistent
with a higher immune tolerance of BALB-neuT mice.
Moreover, 14, 30, and 80 days after last vaccination, the
titer of anti-Her2/neu antibody was evaluated. A significant
Her2/neu specific antibody titer was detected in both BALB/c
(𝑝 = 0,0256) and BALB-neuT (𝑝 = 0,0096) pVAX-ECTM
vaccinated mice as compared to pVAX groups (Figures
5(b) and 5(c)) already after 14 days. Interestingly the titer
remained elevated also 30 days after the vaccination (BALB/c
𝑝 = 0,0242, BALB-neuT 𝑝 = 0,0197), with detectable
high levels up to 100 days after vaccination (not shown)
in all surviving mice. The induction and persistence of the
humoral response in both mouse models, together with the
similar isotype profiling of anti-Her2/neu reactive antibodies
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Figure 2: APCs infiltrate vaccinated skin. Six hours after intradermal EP vaccination dendritic (a) and CD4 (b) cells infiltrate the
electroporated skin and decrease starting at 24 hours after treatment ((c), (d)). Red staining shows positivity for CD11 ((a), (c)) or CD4
((b), (d)) molecule. Magnification: ×200, insets: ×400. Images are representative of three independent experiments.
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Figure 3: Intradermal EP vaccination transfects dendritic cells that migrate to draining lymph nodes. Transfected (red) muscle fibers and
cells (arrows) in skin. Nuclei are shown in green. Magnification ×400. (a) Transfected dendritic cells have migrated into lymph nodes (CD11c
in green, EGFP in red). (b) Interaction of dendritic cells that have incorporated EGFP (in red) with CD4 cells (in green) (c). Transfected cells
(in red) adjacent to B220 cells (in green) in draining lymph node. (d) Nuclei are shown in blue, magnification ×630. ((b)–(d)) Images are
representative of three independent experiments.
(Figures 5(d) and 5(e)), indicate that this type of immu-
nity is similarly triggered in both tolerant and nontolerant
mice. Interestingly a high antibody titer correlated with
tumor protection in BALB-neuT mice (see Supplementary
Figure 1 in Supplementary Material available online at
http://dx.doi.org/10.1155/2015/159145). It is important to note
that naked DNA injection resulted in negligible antibody or
cytotoxicity induction and tumor protection (Supplementary
Figure 2).
Altogether these results indicate that our vaccination
protocol is able to induce a protective immune response not
only in Her-2 nontolerant BALB/c mice, but also in tolerant
BALB-neuT mice.
4. Discussion
By virtue of its versatility and efficacy in inducing immunity
against selected antigens, DNA vaccination represents a
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Figure 4: Intradermal EP vaccination protects BALB/c and BALB-neuT mice against a TUBO challenge. Mice were immunized twice with
empty (pVAX, gray line) or ECTM (pVAX-ECTM, black line) plasmid. pVAX-ECTM treated BALB/c mice (𝑛 = 12) display total tumor
protection ((a), 𝑝 < 0,0001), while control group (𝑛 = 10) develops fast growing tumors within 30 days after challenge ((b), 𝑝 = 0,0003).
Vaccinated BALB-neuT mice (𝑛 = 7) display a delayed tumor onset ((c), 𝑝 = 0,0030) and slower tumor growth (𝑝 < 0,0016) with respect
to control group (𝑛 = 8). Each line refers to an individual tumor. Log-rank (Mantel-Cox) test and Student’s 𝑡-test were used for statistical
analysis.
suitable approach and may provide new therapeutic avenues
for the treatment of tumors [25]. Plasmids can be delivered
by intramuscular, intradermal/epidermal, subcutaneous, oral
(e.g., with bacterial carrier), and pulmonary (e.g., aerosols)
or other routes (e.g., vaginal) [26]. Notably, the skin is a
particularly attractive site for vaccination given that intra-
dermal vaccination is easy to perform and well tolerated
both clinically and histopathologically [17]. Additionally, skin
is characterized by an extended local network of dendritic
cells and the easy access to the skin-draining lymph nodes
generates effector T cells and immunoglobulin-producing
B cells [27, 28]. These characteristics may help the gen-
eration of a long-term protective immunity [29, 30]. In
fact, experiments with bone marrow chimeras have shown
that APCs, presumably dendritic cells, have a key role in
DNA vaccination-induced protection [26]. Moreover, it is
already known that using intradermal EP vaccination a wide
variety of cell types can be transfected and these cells can be
found in the draining afferent lymph nodes, suggesting that
migration of directly transfected dendritic cells may occur
[17]. Nevertheless, intradermal vaccination is notorious for its
lower antibody responses compared to intramuscular route of
plasmid administration in mice [31–34].
In this study we demonstrate that intradermal in vivo
application of pulsed electric field confers long-term protec-
tion from Her2/neu tumor. Indeed, we report that efficiently
permeabilized cells are found in all layers of the skin and
migrate to draining lymph nodes.This is consistent with pre-
vious studies showing that, in contrast to the predominantly
epidermal injection of naked DNA [35], a pattern of dermal
and subdermal transfection is observed in the skin [10].
Concordantly with our data (Figures 1 and 2) transfected cell
types included numerous mononuclear cells with dendritic
morphology, as well as large numbers of adipocytes [17]. The
variety of transfected cell types is likely to grant themounting
of an effective and durable immune response: in fact it has
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Figure 5: Intradermal EP vaccination induces cellular response inHer2/neu nontolerantmice and humoral immune response in both tolerant
and nontolerant mice. In vivo cytotoxicity against the H-2d dominant peptide in BALB/c and BALB-neuT (each experimental group 𝑛 = 3)
mice vaccinated with pVAX (gray bars) or pVAX-ECTM plasmid (black bars). Data are reported as % of lysis. ∗𝑝 = 0,0369, Student’s 𝑡-test.
(a) Anti-Her2/neu antibody titer (MFI ± SEM) in BALB/c (b) and BALB-neuTmice (c). ∗∗𝑝 = 0,0096, ∗𝑝 < 0,0242, Student’s 𝑡-test ((b), (c)).
Isotype titration, performed in three different pools of sera, revealed similar composition of Her2/neu specific antibodies for BALB/c (d) and
BALB-neuT (e) treated mice ((d), (e)).
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been demonstrated that transfection of different cell types
results into different immune responses [36–39].
We further demonstrated that CD11c are efficiently per-
meabilized and hopefully transfected upon DNA vaccina-
tion (Figure 3 and Supplementary Figure 2) as a result of
electroporation. The preferential EP mediated transfection
of cells with dendritic morphology could provide a distinct
advantage due to the central role of such cells in the stim-
ulation of both primary and secondary immune responses
[17]. Dendritic cells are the key initiators and regulators of any
immune response which determine the outcome of CD4 and
CD8 T cell responses [30]. Nevertheless, given the fact that
either direct transfection of APCs or uptake of protein from
other transfected cells (cross presentation) [26] may occur,
we cannot provide formal proof that, although efficiently
permeabilized, skin APCs are directly transfected. However,
either pathway may lead to an effective protection. In fact
it has been demonstrated that, in response to vaccination,
the cutaneous immune system sets up complex mechanisms
including (1) recognition and capture of the vaccine by skin-
resident APCs or by recruited innate immune cells (inflam-
matory microenvironment), (2) activation of skin APCs, (3)
passive diffusion or cell transport of antigens to the secondary
lymphoid organs draining the skin (draining lymph nodes),
(4) processing and presentation of the antigens to immature
CD4 and CD8 T cells by activated APCs or to naive follicular
B cells, (5) activation of antigen-specific CD4 andCD8T cells
and clonal expansion as well as activation of specific B cells
within a germinative center, (6) migration of specific effector
CD4 and CD8 T and B cells toward the zone of vaccination
and elimination of the vaccine antigens, (7) generation of a
pool of specific memory T and B cells in the secondary lym-
phoid organs and in the periphery (skin and mucosa) [30].
Indeed, in our study, after intradermal EP vaccination, a
significant number of reactive cells were already observed at 6
hours after treatment, consisting primarily of dendritic cells.
Independent on the mechanism by which APCs acquire
and then present the target antigen, to the best of our
knowledge, this is the first report showing that intradermal
DNA injection targeting Her2/neu followed by EP elicts a
strong inflammatory-like response and induces both CTL
and antibody responses in BALB/c and humoral response
in tolerant BALB-neuT mice. This is consistent with recent
reports of the presence of both CTL and antibody responses
after vaccination in other tumor models [40, 41]. A previous
study suggested that intradermal plasmid injection could not
induce an effective immune response in Her2/neu models
[25]. Nevertheless, our study demonstrates that, similar to
what have been reported for intramuscular route, electropo-
ration boosts the efficacy of ECTM vaccination when intra-
dermally administered (Supplementary Figure 1), resulting
in a specific immunity and tumor protection. Additionally,
previous studies demonstrated that, in BALB-neuT mice,
intramuscular ECTM injection followed byEP repeated every
10 weeks triggered a humoral response that inhibited the
progression of spontaneous mammary carcinogenesis [10].
Although we cannot directly compare the two methods,
in our study, a single cycle of intradermal EP vaccination
induced a significant delay in tumor onset with an antibody
titre that remains high over time, indicating intradermal
route as a valid alternative to induce Her2/neu specific
response. This data confirms previous studies implicating
anti-Her2/neu antibodies in the inhibition of Her2/neu-
driven carcinogenesis and progression [7, 22, 42, 43]. The
importance of antibodies is further underlined by the
reported absence of protection in BALB-neuT/𝜇KO mice
unable to produce antibodies toHer2/neu after intramuscular
DNA vaccinations with ECTM plasmid [30]. Moreover, the
high titer of anti-Her2/neu antibodies has been demonstrated
to correlate with the downregulation of Her2/neu in the
cells of mammary lesions and its cytoplasmic confinement
[21, 43, 44]. Consistent with a central role of antibody-
mediated protection [45–48] we observed protection from
tumor challenge in BALB-neuT mice even in the absence of
cell cytotoxicity, and long-term survivor mice displayed the
highest antibody titer (Supplementary Figure 2).
Notably in our study we were able to achieve a long-
term protection not only in Her2/neu nontolerant BALB/c
mice that are more prone to mount an effective immune
response against the oncogene (as demonstrated also by
the capability of our vaccination to induce cytotoxicity in
these mice), but also in highly tolerant BALB-neuT mice.
BALB-neuT mice are genetically predestined to develop
lethal invasive carcinomas in their mammary glands by week
22 [10]. As the transforming (and immunization target)
oncogene is embedded in the genome of these mice, a unique
dynamic relationship between the oncogenic signals and
inhibitory immune reactions is taking place. Given the long-
term protection achieved with only 2 vaccination rounds,
it will be of interest to test our experimental setting on
spontaneousHer2/neu positivemammary tumors to evaluate
if intradermal EP vaccination can reduce the number of doses
and/or prolong the tumor-free mice. In fact, prolongation
of immune memory could be even a more worthwhile goal
than enhancement of the immune response [42]. Indeed,
activating the appropriate arm of the immune system that
induces protection is now one of the major challenges to
be faced in vaccine development against tumors. However,
further studies are necessary to find out the best settings
for vaccination, such as the nature of the antigens, against
which immune responses are elicited, the use of adjuvant, and
specific delivery system that will ensure optimal presentation
to immune system and protection from tumors.
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